Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

PHASE2CompletedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

March 31, 2010

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

BI 1744 CL 2 µg

2 puffs of 1 µg/actuation delivered by the Respimat® inhaler

DRUG

BI 1744 CL 5 µg

2 puffs of 2.5 µg/actuation delivered by the Respimat® inhaler

DRUG

BI 1744 CL 10 µg

2 puffs of 5 µg/actuation delivered by Respimat®

DRUG

Placebo

2 puffs delivered by the Respimat® inhaler

Trial Locations (48)

Unknown

1222.22.048 Boehringer Ingelheim Investigational Site, Asahikawa, Hokkaido

1222.22.044 Boehringer Ingelheim Investigational Site, Bunkyo-ku, Tokyo

1222.22.008 Boehringer Ingelheim Investigational Site, Chiba, Chiba

1222.22.002 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1222.22.041 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1222.22.027 Boehringer Ingelheim Investigational Site, Himeji, Hyogo

1222.22.028 Boehringer Ingelheim Investigational Site, Himeji, Hyogo

1222.22.018 Boehringer Ingelheim Investigational Site, Hiroshima, Hiroshima

1222.22.021 Boehringer Ingelheim Investigational Site, Hitachi, Ibaraki

1222.22.010 Boehringer Ingelheim Investigational Site, Inashiki-gun, Ibaraki

1222.22.012 Boehringer Ingelheim Investigational Site, Itabashi-ku, Tokyo

1222.22.009 Boehringer Ingelheim Investigational Site, Kamogawa, Chiba

1222.22.023 Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa

1222.22.025 Boehringer Ingelheim Investigational Site, Kawasaki, Kanagawa

1222.22.017 Boehringer Ingelheim Investigational Site, Kishiwada, Osaka

1222.22.004 Boehringer Ingelheim Investigational Site, Kitakyusyu, Fukuoka

1222.22.020 Boehringer Ingelheim Investigational Site, Koga, Fukuoka

1222.22.014 Boehringer Ingelheim Investigational Site, Komaki, Aichi

1222.22.032 Boehringer Ingelheim Investigational Site, Kumamoto, Kumamoto

1222.22.005 Boehringer Ingelheim Investigational Site, Kurume, Fukuoka

1222.22.029 Boehringer Ingelheim Investigational Site, Kurume, Fukuoka

1222.22.033 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

1222.22.050 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

1222.22.022 Boehringer Ingelheim Investigational Site, Matsumoto, Nagano

1222.22.015 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1222.22.043 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1222.22.001 Boehringer Ingelheim Investigational Site, Naka-gun, Ibaraki

1222.22.007 Boehringer Ingelheim Investigational Site, Niigata, Niigata

1222.22.040 Boehringer Ingelheim Investigational Site, Obihiro, Hokkaido

1222.22.042 Boehringer Ingelheim Investigational Site, Okinawa, Okinawa

1222.22.034 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1222.22.038 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1222.22.049 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1222.22.045 Boehringer Ingelheim Investigational Site, Osaka-sayama, Osaka

1222.22.019 Boehringer Ingelheim Investigational Site, Sakai, Oasaka

1222.22.006 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1222.22.051 Boehringer Ingelheim Investigational Site, Sashima-gun, Ibaraki

1222.22.031 Boehringer Ingelheim Investigational Site, Sendai, Miyagi

1222.22.013 Boehringer Ingelheim Investigational Site, Seto, Aichi

1222.22.024 Boehringer Ingelheim Investigational Site, Shibata-gun, Miyagi

1222.22.003 Boehringer Ingelheim Investigational Site, Takarazuka, Hyogo

1222.22.026 Boehringer Ingelheim Investigational Site, Tsukuba, Ibaraki

1222.22.030 Boehringer Ingelheim Investigational Site, Ube, Yamaguchi

1222.22.037 Boehringer Ingelheim Investigational Site, Uji, Kyoto

1222.22.047 Boehringer Ingelheim Investigational Site, Wakayama, Wakayama

1222.22.016 Boehringer Ingelheim Investigational Site, Yamagata, Yamagata

1222.22.036 Boehringer Ingelheim Investigational Site, Yao, Osaka

1222.22.011 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00824382 - Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD | Biotech Hunter | Biotech Hunter